Full text is available at the source.
Abstract
Dihydromyricetin (DMY) improved depression-like behaviors in a rat model, showing potential for dietary use.
- DMY reduced symptoms of anhedonia, behavioral despair, and cognitive dysfunction in the rat model.
- Circulating pro-inflammatory cytokines and neuronal damage in the hippocampus were decreased with DMY treatment.
- DMY restored gut microbial diversity and composition, affecting bile acid and short-chain fatty acid profiles.
- Fecal microbiota transplantation from DMY-treated rats replicated the antidepressant-like effects and restored important microbial metabolites.
- These findings indicate that DMY may influence depression-like behaviors by modulating gut microbiota and neuroinflammatory responses.
Simplified